Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01842607 · ClinicalTrials.gov registry record · Phase 3
A Study to Determine Long-term Safety of Mepolizumab in Asthmatic Subjects
A Phase 3 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 3
- Development phase
- 651
- Enrollment target
NCT01842607 is a Phase 3 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 651 participants.
The verdict
NCT01842607, a Phase 3 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 651 participants
- Enrollment target
Study Summary
This is a multi-centre, open-label long-term safety study of 100 milligram (mg) mepolizumab administered subcutaneously (SC) every 4 weeks for 12 months in addition to standard of care in subjects who have severe, refractory asthma and a history of eosinophilic inflammation. Subjects who completed either MEA115588 or MEA115575 will be offered the opportunity to consent for this study.
Interventions
- BIOLOGICAL Mepolizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 651 participants |
| Start Date | 2013-05-27 |
| Est. Completion | 2015-03-13 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01842607
The ClinicalTrials.gov registry entry for NCT01842607 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 651 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Mepolizumab is the first listed.
NCT01842607 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01842607 about?
NCT01842607 is a clinical study titled "A Study to Determine Long-term Safety of Mepolizumab in Asthmatic Subjects". This is a multi-centre, open-label long-term safety study of 100 milligram (mg) mepolizumab administered subcutaneously (SC) every 4 weeks for 12 months in addition to standard of care in subjects who have severe, refractory asthma and a history of eosinophilic inflammation. Subjects who completed e...
What is the current status of trial NCT01842607?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 651 participants. The study started on 2013-05-27. Estimated completion is 2015-03-13.
What interventions are being tested in trial NCT01842607?
The interventions under investigation include: Mepolizumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT01842607?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.